Isoniazid Dosage Prediction Model Development
Isoniazid Dosage Prediction Model Development
Isoniazid (INH) is an essential component of first-line anti-tuberculosis (TB) treatment.
 However, treatment with INH is complicated by polymorphisms in the expression of the enzyme
 system primarily responsible for its elimination, N-acetyltransferase 2 (NAT2), and its
 associated hepatotoxicity. The objective of this study was to develop an individualized INH
 dosing regimen using a pharmacogenetic-driven model and to apply this regimen in a pilot
 study.
-  Eligible participants were patients newly diagnosed with active TB

 -  Who underwent standard four drug treatment for 6months: isoniazid (5 mg/kg, usually
 300 mg), rifampin (450 mg for <50 kg or 600 mg for 50 kg body weight),
 ethambutol(15mg/kg), and pyrazinamide (20 - 30 mg/kg)

 -  Given daily for two months and followed by isoniazid and rifampin with or without
 ethambutol for four months.

 -  Those patients with abnormal hepatic function on laboratory testing (increased serum
 aspartate aminotransferase, alanine aminotransferase, or total bilirubin) before
 anti-TB treatment, underlying liver disease or systemic illness such as congestive
 heart failure, acute life-threatening disease, or alcoholism, or disease that was
 resistant to INH at the start of treatment were excluded.